Recent Quotes

My Watchlist

Indicators

Markets:

Overview

News

Currencies

International

Treasuries

Altamira Therapeutics Ltd. - Common Shares (NQ:CYTO)

0.3001 UNCHANGED

Last Price Updated: 3:55 PM EST, Dec 19, 2024 Add to My Watchlist

Price and Volume

Detailed Quote

Volume	0
Open	0.3001
Bid (Size)	0.2800 (2)
Ask (Size)	0.2870 (58)
Prev. Close	0.3001
Today's Range	0.3001 - 0.3001
52wk Range	0.3001 - 0.5750
Shares Outstanding	12,869,587
Dividend Yield	N/A

Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News

Altamira Therapeutics Announces Transition from NASDAQ to OTC Markets

December 20, 2024

From Altamira Therapeutics Ltd

Via GlobeNewswire

12 Health Care Stocks Moving In Wednesday's Pre-Market Session ↗

November 06, 2024

Via Benzinga

Performance

YTD	N/A	N/A
1 Month	N/A	N/A
3 Month	N/A	N/A
6 Month	N/A	N/A
1 Year	-25.5%	-25.5%

More News

Altamira Therapeutics Provides Update on Nasdaq Listing

October 04, 2024

From Altamira Therapeutics Ltd

Via GlobeNewswire

Altamira Therapeutics Announces Extended ISO 13485 Quality Management System Certification for Bentrio Nasal Spray

September 27, 2024

From Altamira Therapeutics Ltd

Via GlobeNewswire

Altamira Therapeutics Provides Business Update and First Half 2024 Financial Results

September 24, 2024

From Altamira Therapeutics Ltd

Via GlobeNewswire

Altamira Therapeutics to Host First Half 2024 Financial Results and Business Update Call on September 24, 2024

September 20, 2024

From Altamira Therapeutics Ltd

Via GlobeNewswire

Altamira Therapeutics Announces Closing of up to $12.0 Million Public Offering

September 19, 2024

From Altamira Therapeutics Ltd

Via GlobeNewswire

Altamira Therapeutics Announces Pricing of up to $12.0 Million Public Offering

September 17, 2024

From Altamira Therapeutics Ltd

Via GlobeNewswire

Altamira Therapeutics Announces Expansion of Bentrio License and Distribution Agreement with Nuance Pharma in East and South East Asia

September 16, 2024

From Altamira Therapeutics Ltd

Via GlobeNewswire

Altamira Therapeutics to Present at H.C. Wainwright 26th Annual Global Investment Conference September 9-11

September 03, 2024

From Altamira Therapeutics Ltd

Via GlobeNewswire

Altamira Therapeutics Announces Extension of Bentrio Distribution Agreement with Pharma Nordic to Include Sweden and Denmark

August 23, 2024

From Altamira Therapeutics Ltd

Via GlobeNewswire

Altamira Therapeutics Announces Confirmed Suitability of Bentrio for Athletes as Comprehensive Testing Shows Absence of Prohibited Substances

August 16, 2024

From Altamira Therapeutics Ltd

Via GlobeNewswire

Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Thursday ↗

August 15, 2024

Via InvestorPlace

Why Lumentum Shares Are Trading Higher By Around 16%; Here Are 20 Stocks Moving Premarket ↗

August 15, 2024

Via Benzinga

Altamira Therapeutics Announces Significant Enhancement of Immune Checkpoint Inhibition Therapy in Combination with Zbtb46 mRNA Delivered with SemaPhore Nanoparticles in Animal Tumor Models

August 12, 2024

From Altamira Therapeutics Ltd

Via GlobeNewswire

Altamira Therapeutics Announces Publication of Preclinical Data Showing Successful Treatment of Abdominal Aortic Aneurysm with SOD2 mRNA Delivered by SemaPhore Nanoparticles

July 19, 2024

From Altamira Therapeutics Ltd

Via GlobeNewswire

Altamira Therapeutics Highlights Newly Published Review Article Supporting Use of Betahistine in Vertigo Management

June 20, 2024

From Altamira Therapeutics Ltd

Via GlobeNewswire

Altamira Therapeutics Provides Business Update

May 28, 2024

From Altamira Therapeutics Ltd

Via GlobeNewswire

Hunting For Gains In Penny Stocks ↗

May 26, 2024

Via Talk Markets

Biotechs Zero in on New Pancreatic Therapies as Global Pancreatic Cancer Market Expected Reach to $7.4 Billion By 2032

May 24, 2024

Via FinancialNewsMedia

12 Health Care Stocks Moving In Thursday's Intraday Session ↗

May 23, 2024

Via Benzinga

Biotechs Zero in on New Pancreatic Therapies as Global Pancreatic Cancer Market Expected Reach to $7.4 Billion By 2032

May 24, 2024

From FN Media Group LLC

Via GlobeNewswire

What's Going On With Altamira Therapeutics Stock? ↗

May 23, 2024

Via Benzinga

Altamira Therapeutics Announces Dissemination of Positive Results from Bentrio Trial in Seasonal Allergic Rhinitis Through Social Media Channels of Top Allergy Journal

May 23, 2024

From Altamira Therapeutics Ltd

Via GlobeNewswire

Altamira Therapeutics Announces Filing of Provisional Patent Application for OligoPhore Nanoparticles with siRNA Targeting p65 Protein in Treatment of Cancer and Inflammation

May 01, 2024

From Altamira Therapeutics Ltd

Via GlobeNewswire

Frequently Asked Questions

Is Altamira Therapeutics Ltd. - Common Shares publicly traded?

Yes, Altamira Therapeutics Ltd. - Common Shares is publicly traded.

What exchange does Altamira Therapeutics Ltd. - Common Shares trade on?

Altamira Therapeutics Ltd. - Common Shares trades on the Nasdaq Stock Market

What is the ticker symbol for Altamira Therapeutics Ltd. - Common Shares?

The ticker symbol for Altamira Therapeutics Ltd. - Common Shares is CYTO on the Nasdaq Stock Market

What is the current price of Altamira Therapeutics Ltd. - Common Shares?

The current price of Altamira Therapeutics Ltd. - Common Shares is 0.3001

When was Altamira Therapeutics Ltd. - Common Shares last traded?

The last trade of Altamira Therapeutics Ltd. - Common Shares was at 12/19/24 03:55 PM ET

What is the market capitalization of Altamira Therapeutics Ltd. - Common Shares?

The market capitalization of Altamira Therapeutics Ltd. - Common Shares is 3.86M

How many shares of Altamira Therapeutics Ltd. - Common Shares are outstanding?

Altamira Therapeutics Ltd. - Common Shares has 4M shares outstanding.

Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.